International Severe Asthma Registry: Canadian Cohort
The International Severe Asthma Registry is a global initiative looking to ensure that the care of people with severe asthma will continue to improve by collecting detailed information about the health and treatment of as many people with the disease as possible. The study will gather anonymized longitudinal real-life data for participants with severe asthma for five years. The purpose of the registry is to track the progress of participants and determine how well they are responding to treatment. Medical research…
Conditions studied
Severe Asthma
About this study
The International Severe Asthma Registry is a global initiative looking to ensure that the care of people with severe asthma will continue to improve by collecting detailed information about the health and treatment of as many people with the disease as possible. The study will gather anonymized longitudinal real-life data for participants with severe asthma for five years. The purpose of the registry is to track the progress of participants and determine how well they are responding to treatment. Medical research using data from the registry will give the investigators a better understanding of severe asthma and help the investigators develop and improve the care and treatment for severe asthma participants. The Canadian cohort of the registry will collect information from Canadian participants with severe asthma across seven different sites.
Primary outcomes
- Blood eosinophil counts (Past 12 months)
- Blood Immunoglobulin E (IgE) counts (Past 12 months)
- Fractional exhaled nitric oxide level (Past 12 months)
- Start and end dates of oral corticosteroid medication (Prior to baseline visit)
- Asthma Control (Past 4 weeks)
- Start and end dates of biologic medications such as anti-interleukin-5, anti-immunoglobulin E, or anti-interleukin-4 treatments (if relevant) (Prior to baseline visit)
- Reason for switching biologic medication (if relevant) (Past 12 months)
- Start and end dates of all asthma related inhaled medications (Prior to baseline visit)
Eligibility information
Study locations
- University of Alberta, Edmonton, Alberta T6G2G3 Canada
- Synergy MD Specialty Group, Edmonton, Alberta Canada
- University of British Columbia, Vancouver, British Columbia V5Z1M9 Canada
- University of British Columbia, Vancouver, British Columbia V6Z1Y6 Canada
- Kingston General Hospital, Kingston, Ontario Canada
- University of Western Ontario, London, Ontario Canada
- The Ottawa Hospital, Ottawa, Ontario Canada
- Inspiration Research Limited, Toronto, Ontario M5T3A9 Canada
- McGill University, Montreal, Quebec H4A3J1 Canada
- Université de Sherbrooke, Sherbrooke, Quebec Canada
Showing 10 of 12 reported sites. See the official listing for all locations.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-05.